

Alan Spatz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8626787/publications.pdf>

Version: 2024-02-01

168
papers

11,983
citations

31976

53
h-index

28297

105
g-index

175
all docs

175
docs citations

175
times ranked

14159
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. <i>Journal of Translational Medicine</i> , 2005, 3, 10.	4.4	993
2	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. <i>Lancet</i> , The, 2008, 372, 117-126.	13.7	620
3	Cutaneous side-effects of kinase inhibitors and blocking antibodies. <i>Lancet Oncology</i> , The, 2005, 6, 491-500.	10.7	527
4	Cutaneous melanoma. <i>Lancet</i> , The, 2014, 383, 816-827.	13.7	465
5	Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome. <i>Journal of the National Cancer Institute</i> , 2006, 98, 472-482.	6.3	457
6	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012. <i>European Journal of Cancer</i> , 2012, 48, 2375-2390.	2.8	407
7	Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group [published erratum appears in <i>Hum Mol Genet</i> 1998 May;7(5):941]. <i>Human Molecular Genetics</i> , 1998, 7, 209-216.	2.9	345
8	Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2010, 46, 270-283.	2.8	284
9	Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3810-3818.	1.6	254
10	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. <i>Journal of Clinical Investigation</i> , 2004, 114, 379-388.	8.2	248
11	High expression of DNA repair pathways is associated with metastasis in melanoma patients. <i>Oncogene</i> , 2008, 27, 565-573.	5.9	228
12	Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor. <i>Archives of Dermatology</i> , 2008, 144, 886-92.	1.4	204
13	Spitz Tumors in Children. <i>Archives of Dermatology</i> , 1999, 135, 282-5.	1.4	197
14	Prognosis in Patients With Sentinel Node-Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria. <i>Journal of Clinical Oncology</i> , 2011, 29, 2206-2214.	1.6	195
15	The development of optimal pathological assessment of sentinel lymph nodes for melanoma. <i>Journal of Pathology</i> , 2003, 200, 314-319.	4.5	193
16	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). <i>European Journal of Cancer</i> , 2011, 47, 1476-1483.	2.8	189
17	Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2413-2420.	1.6	188
18	Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. <i>European Journal of Cancer</i> , 2012, 48, 218-225.	2.8	182

#	ARTICLE	IF	CITATIONS
19	X-Chromosome Genetics and Human Cancer. <i>Nature Reviews Cancer</i> , 2004, 4, 617-629.	28.4	162
20	EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1713-1742.	6.4	159
21	Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib. <i>Journal of Clinical Oncology</i> , 2009, 27, e59-e61.	1.6	152
22	The validity of circulating microRNAs in oncology: Five years of challenges and contradictions. <i>Molecular Oncology</i> , 2014, 8, 819-829.	4.6	149
23	Dermatologic symptoms associated with the multikinase inhibitor sorafenib. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 299-305.	1.2	142
24	Genetic and morphologic features for melanoma classification. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 763-770.	3.3	130
25	Value of high-frequency US for preoperative assessment of skin tumors.. <i>Radiographics</i> , 1997, 17, 1559-1565.	3.3	124
26	Differentiation between recurrent tumor and benign conditions after treatment of gynecologic pelvic carcinoma: value of dynamic contrast-enhanced subtraction MR imaging.. <i>Radiology</i> , 1997, 204, 55-63.	7.3	123
27	Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 2916-2923.	1.6	119
28	Skin Tumors Induced by Sorafenib; Paradoxical RAS-RAF Pathway Activation and Oncogenic Mutations of <i>HRAS</i> , <i>TP53</i> , and <i>TGFBR1</i> . <i>Clinical Cancer Research</i> , 2012, 18, 263-272.	7.0	119
29	Biomarkers in melanoma. <i>Annals of Oncology</i> , 2009, 20, vi8-vi13.	1.2	118
30	Dendritic cell derived-exosomes: biology and clinical implementations. <i>Journal of Leukocyte Biology</i> , 2006, 80, 471-478.	3.3	117
31	Biopsies: next-generation biospecimens for tailoring therapy. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 437-450.	27.6	110
32	The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 268-273.	1.3	100
33	Influence of Genes, Nevi, and Sun Sensitivity on Melanoma Risk in a Family Sample Unselected by Family History and in Melanoma-Prone Families. <i>Journal of the National Cancer Institute</i> , 2004, 96, 785-795.	6.3	97
34	Melanoma in childhood: An EORTC-MCG multicenter study on the clinico-pathological aspects. , 1996, 68, 317-324.		94
35	Selective Accumulation of Mature DC-Lamp+ Dendritic Cells in Tumor Sites Is Associated with Efficient T-Cell-Mediated Antitumor Response and Control of Metastatic Dissemination in Melanoma. <i>Cancer Research</i> , 2004, 64, 2192-2198.	0.9	94
36	Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1417-1422.	1.2	92

#	ARTICLE	IF	CITATIONS
37	Intratumoral oxygen tension in metastatic melanoma. <i>Melanoma Research</i> , 1997, 7, 400-406.	1.2	89
38	Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3831-3837.	1.6	88
39	TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network. <i>European Journal of Cancer</i> , 2006, 42, 2684-2691.	2.8	84
40	Reliability of the Histopathologic Diagnosis of Malignant Melanoma in Childhood. <i>Archives of Dermatology</i> , 2002, 138, 625.	1.4	83
41	Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. <i>European Journal of Cancer</i> , 2003, 39, 1861-1865.	2.8	81
42	The Janus face of dendritic cells in cancer. <i>Oncogene</i> , 2008, 27, 5920-5931.	5.9	80
43	Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon. <i>Journal of the National Cancer Institute</i> , 2009, 101, 869-877.	6.3	72
44	Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodiesâ€”EORTC 18991. <i>Journal of Clinical Oncology</i> , 2010, 28, 2460-2466.	1.6	69
45	Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period. <i>Cancer Imaging</i> , 2006, 6, 24-29.	2.8	68
46	Long-Term Protective Effect of Mature DC-LAMP+ Dendritic Cell Accumulation in Sentinel Lymph Nodes Containing Micrometastatic Melanoma. <i>Clinical Cancer Research</i> , 2007, 13, 3825-3830.	7.0	67
47	Factors to keep in mind when introducing virtual microscopy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 248-255.	2.8	66
48	Sporadic multiple primary melanoma cases:CDKN2Agermline mutations with a founder effect. <i>Genes Chromosomes and Cancer</i> , 2001, 32, 195-202.	2.8	63
49	Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm: a prospective study of 41 patients.. <i>Radiology</i> , 1996, 200, 453-458.	7.3	62
50	TuBaFrost 3: Regulatory and ethical issues on the exchange of residual tissue for research across Europe. <i>European Journal of Cancer</i> , 2006, 42, 2914-2923.	2.8	62
51	Spatially mapping the immune landscape of melanoma using imaging mass cytometry. <i>Science Immunology</i> , 2022, 7, eabi5072.	11.9	60
52	BORIS/CTCFL promotes a switch from a proliferative towards an invasive phenotype in melanoma cells. <i>Cell Death Discovery</i> , 2020, 6, 1.	4.7	59
53	The Spitz tumor 50 years later: Revisiting a landmark contribution and unresolved controversy. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, 223-228.	1.2	58
54	Microcystic Adnexal Carcinoma: Report of Seven Cases Including One with Lung Metastasis. <i>Dermatology</i> , 2006, 212, 221-228.	2.1	58

#	ARTICLE	IF	CITATIONS
55	Pathologic staging of melanoma. <i>Seminars in Oncology</i> , 2002, 29, 370-381.	2.2	56
56	Expert opinion in melanoma: The sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. <i>European Journal of Cancer</i> , 2009, 45, 2736-2742.	2.8	56
57	EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?. <i>British Journal of Cancer</i> , 2012, 107, 1864-1868.	6.4	56
58	Identification of histological features associated with metastatic potential in thin (<1.0â€‰mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group. <i>Journal of Pathology</i> , 2002, 197, 188-193.	4.5	55
59	Clinical and Histopathological Characterization of Cutaneous Melanomas in the Melanoblastoma-Bearing Libechev Minipig Model. <i>Pigment Cell & Melanoma Research</i> , 2004, 17, 24-35.	3.6	54
60	Malignant Blue Nevus of the Vulva With Late Ovarian Metastasis. <i>American Journal of Dermatopathology</i> , 1998, 20, 408-412.	0.6	53
61	Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene. <i>Carcinogenesis</i> , 2006, 28, 724-731.	2.8	52
62	F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4â€‰mm. <i>Melanoma Research</i> , 2007, 17, 147-154.	1.2	51
63	Plexiform Spitz Nevus. <i>American Journal of Dermatopathology</i> , 1999, 21, 542.	0.6	51
64	Indium-III octreotide scintigraphy of Merkel cell carcinomas and their metastases. <i>Annals of Oncology</i> , 2001, 12, 807-811.	1.2	50
65	Tyrosine kinase inhibition and grey hair. <i>Lancet, The</i> , 2003, 361, 1056.	13.7	50
66	Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. <i>Journal of Medical Genetics</i> , 2005, 43, 39-47.	3.2	50
67	Borderline and Malignant Serous Tumor Arising in Pelvic Lymph Nodes. <i>International Journal of Gynecological Pathology</i> , 1995, 14, 87-91.	1.4	49
68	Skin cancer incidence and survival in European children and adolescents (1978â€“1997). Report from the Automated Childhood Cancer Information System project. <i>European Journal of Cancer</i> , 2006, 42, 2170-2182.	2.8	49
69	Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 441-448.	2.8	49
70	Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). <i>European Journal of Cancer</i> , 2009, 45, 3189-3197.	2.8	48
71	Gene expression signature associated with <i>BRAF</i> mutations in human primary cutaneous melanomas. <i>Molecular Oncology</i> , 2008, 1, 425-430.	4.6	47
72	Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. , 2017, 5, 83.		46

#	ARTICLE	IF	CITATIONS
73	Primary Yolk Sac Tumor of the Endometrium: A Case Report and Review of the Literature. <i>Gynecologic Oncology</i> , 1998, 70, 285-288.	1.4	43
74	Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?. <i>Current Opinion in Oncology</i> , 2012, 24, 137-140.	2.4	43
75	TuBaFrost 1: Uniting local Frozen Tumour Banks into a European Network: an overview. <i>European Journal of Cancer</i> , 2006, 42, 2678-2683.	2.8	39
76	Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (>â€Œ5â€Œmm). <i>Histopathology</i> , 1998, 33, 406-413.	2.9	38
77	The biology behind prognostic factors of cutaneous melanoma. <i>Current Opinion in Oncology</i> , 2010, 22, 163-168.	2.4	37
78	BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. <i>Familial Cancer</i> , 2007, 6, 453-461.	1.9	36
79	Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine. <i>Modern Pathology</i> , 2013, 26, 1413-1424.	5.5	35
80	A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology. <i>Current Oncology</i> , 2019, 26, 241-254.	2.2	34
81	Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up care. <i>BMC Dermatology</i> , 2013, 13, 3.	2.1	33
82	The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. <i>Science Translational Medicine</i> , 2016, 8, 369ra177.	12.4	33
83	Human Melanoma Cell Migration Along Capillary-Like Structures In Vitro: A New Dynamic Model for Studying Extravascular Migratory Metastasis. <i>Journal of Investigative Dermatology</i> , 2002, 119, 703-704.	0.7	31
84	CDKN2A as a uveal and cutaneous melanoma susceptibility gene. <i>Genes Chromosomes and Cancer</i> , 2003, 38, 265-268.	2.8	31
85	In vivo evolution of tumour cells after the generation of double-strand DNA breaks. <i>British Journal of Cancer</i> , 2003, 88, 1763-1771.	6.4	31
86	Selective expression of inhibitory FcÎ³ receptor by metastatic melanoma impairs tumor susceptibility to IgGâ€Œdependent cellular response. <i>International Journal of Cancer</i> , 2008, 123, 2832-2839.	5.1	31
87	Gene expression profiling of human angiotropic primary melanoma: Selection of 15 differentially expressed genes potentially involved in extravascular migratory metastasis. <i>European Journal of Cancer</i> , 2011, 47, 1267-1275.	2.8	31
88	TuBaFrost 6: Virtual microscopy in virtual tumour banking. <i>European Journal of Cancer</i> , 2006, 42, 3110-3116.	2.8	30
89	Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada. <i>Current Oncology</i> , 2018, 25, 163-169.	2.2	28
90	Human tissue research. <i>European Journal of Cancer</i> , 2003, 39, 2256-2263.	2.8	26

#	ARTICLE	IF	CITATIONS
91	Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma. <i>Nature Cancer</i> , 2020, 1, 635-652.	13.2	26
92	Expression and possible role of hPTTG1/securin in cutaneous malignant melanoma. <i>Modern Pathology</i> , 2006, 19, 1170-1180.	5.5	25
93	The Role of Molecular Pathology in Non-Small-Cell Lung Carcinoma—Now and in the Future. <i>Current Oncology</i> , 2012, 19, 24-32.	2.2	25
94	TuBaFrost 4: Access rules and incentives for a European tumour bank. <i>European Journal of Cancer</i> , 2006, 42, 2924-2929.	2.8	24
95	TuBaFrost 5: Multifunctional central database application for a European tumor bank. <i>European Journal of Cancer</i> , 2006, 42, 3103-3109.	2.8	24
96	Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients. <i>Oncogene</i> , 2008, 27, 5223-5232.	5.9	22
97	The dual role of the X-linked FoxP3 gene in human cancers. <i>Molecular Oncology</i> , 2011, 5, 156-163.	4.6	21
98	Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients. <i>British Journal of Cancer</i> , 2013, 108, 1641-1647.	6.4	20
99	How iMALDI can improve clinical diagnostics. <i>Analyst, The</i> , 2018, 143, 2197-2203.	3.5	20
100	Hepatocellular Carcinoma During Hormonotherapy for Prostatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994, 17, 390-392.	1.3	19
101	Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies. <i>Frontiers in Pharmacology</i> , 2011, 2, 59.	3.5	19
102	The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma. <i>Lung Cancer</i> , 2019, 132, 36-38.	2.0	19
103	Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1328-1337.	1.1	19
104	Soft Tissue Sarcomas. <i>Journal of Clinical Oncology</i> , 2004, 22, 2029-2031.	1.6	18
105	Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1628-1636.	4.1	18
106	Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 160, 127-135.	2.0	16
107	Melanoma in Childhood: Review and Perspectives. <i>Pediatric and Developmental Pathology</i> , 1998, 1, 463-474.	1.0	15
108	An explosive course of squamous cell penile cancer in an AIDS patient. <i>Annals of Oncology</i> , 2002, 13, 475-479.	1.2	15

#	ARTICLE	IF	CITATIONS
109	EGFR Tyrosine Kinase Mutation Testing in the Treatment of Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2012, 19, 67-74.	2.2	15
110	Melanoma arising de novo in childhood: experience of the Gustave-Roussy Institute. <i>Melanoma Research</i> , 1995, 5, 117-122.	1.2	12
111	Heterozygous mutations in the tumor suppressor gene PATCHED provoke basal cell carcinoma-like features in human organotypic skin cultures. <i>Oncogene</i> , 2008, 27, 6601-6606.	5.9	12
112	Proteogenomics of Colorectal Cancer Liver Metastases: Complementing Precision Oncology with Phenotypic Data. <i>Cancers</i> , 2019, 11, 1907.	3.7	12
113	Virtual Microscopy in Virtual Tumor Banking. <i>Advances in Experimental Medicine and Biology</i> , 2006, 587, 75-86.	1.6	12
114	Nucleolar Organizer Regions in Ovarian Tumors. <i>International Journal of Gynecological Pathology</i> , 1992, 11, 11-14.	1.4	11
115	Eccrine porocarcinoma with intracerebral extension. <i>European Radiology</i> , 1997, 7, 573-575.	4.5	11
116	Comparative genomic hybridization analysis of hereditary swine cutaneous melanoma revealed loss of the swine 13q36-49 chromosomal region in the nodular melanoma subtype. <i>International Journal of Cancer</i> , 2004, 110, 232-238.	5.1	11
117	The potential contribution of fluorescent <i>in situ</i> hybridization analysis to the cytopathological diagnosis of Merkel cell carcinoma. <i>Cytopathology</i> , 2008, 19, 48-51.	0.7	11
118	Maximizing confidence in a negative result: Quantitative sample adequacy control. <i>Journal of Infection and Public Health</i> , 2020, 13, 991-993.	4.1	11
119	An experimental inter-expert telepathology network using static imaging. <i>Journal of Clinical Pathology</i> , 2001, 54, 752-757.	2.0	11
120	Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM). <i>Journal of Clinical Oncology</i> , 2013, 31, 9032-9032.	1.6	10
121	The biology of melanoma prognostic factors. <i>Discovery Medicine</i> , 2010, 10, 87-93.	0.5	10
122	Association between germ cell tumours, large numbers of naevi, atypical naevi and melanoma. <i>Melanoma Research</i> , 2001, 11, 117-122.	1.2	9
123	Microstaging in cutaneous melanoma. <i>Journal of Pathology</i> , 2001, 195, 525-529.	4.5	9
124	Reply to F. Janku et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e17-e18.	1.6	9
125	Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e161-e163.	1.1	9
126	Reproducibility of Histopathologic Diagnosis and Classification of Non-Melanocytic Skin Cancer: A Panel Exercise in the Framework of the Multicenter Southern European Study Helios. <i>Tumori</i> , 2001, 87, 95-100.	1.1	8

#	ARTICLE	IF	CITATIONS
127	Precise Quantitation of PTEN by Immuno-MRM: A Tool To Resolve the Breast Cancer Biomarker Controversy. <i>Analytical Chemistry</i> , 2021, 93, 10816-10824.	6.5	7
128	A Non-Hazardous Deparaffinization Protocol Enables Quantitative Proteomics of Core Needle Biopsy-Sized Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Specimens. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4443.	4.1	7
129	Tumour budding predicts increased recurrence after curative resection for T2N0 colorectal cancer. <i>Canadian Journal of Surgery</i> , 2019, 62, 334-339.	1.2	6
130	Direct and Precise Measurement of Bevacizumab Levels in Human Plasma Based on Controlled Methionine Oxidation and Multiple Reaction Monitoring. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1304-1309.	4.9	6
131	Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study). <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1223-1233.	4.2	5
132	Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. <i>Human Pathology</i> , 2014, 45, 2006-2013.	2.0	5
133	Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer Cells. <i>Proteomics - Clinical Applications</i> , 2020, 14, 2000034.	1.6	5
134	Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning Models. <i>Cancers</i> , 2021, 13, 3723.	3.7	5
135	Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy Analysis of two cases, literature review and surgical implications. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2004, 113, 251-254.	1.1	4
136	The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. <i>Journal of Cutaneous Pathology</i> , 2006, 33, 397-399.	1.3	4
137	Molecular pathology of cutaneous melanoma. <i>Melanoma Management</i> , 2014, 1, 151-164.	0.5	4
138	Laboratory-developed test for detection of acute <i>Clostridium difficile</i> infections with the capacity for quantitative sample normalization. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 95, 113-118.	1.8	4
139	Revitalising an academic pathology department: lessons learnt. <i>Journal of Clinical Pathology</i> , 2019, 72, 213-220.	2.0	4
140	A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9066-9066.	1.6	4
141	From biomarker development towards implementation of multidimensional biomarker panels in a clinical setting. <i>Molecular Oncology</i> , 2014, 8, 781-782.	4.6	3
142	Do clinical criteria reflect pathologic complete response in rectal cancer following neoadjuvant therapy?. <i>International Journal of Colorectal Disease</i> , 2018, 33, 727-733.	2.2	3
143	Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition. <i>Clinical Proteomics</i> , 2020, 17, 5.	2.1	3
144	Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLC. <i>Oncotarget</i> , 2018, 9, 35472-35473.	1.8	3

#	ARTICLE	IF	CITATIONS
145	NEDD9 links anaplastic thyroid cancer stemness to chromosomal instability through integrated centrosome asymmetry and DNA sensing regulation. <i>Oncogene</i> , 2022, 41, 2984-2999.	5.9	3
146	Melanoma "The pieces of the puzzle finally start coming together!. <i>Molecular Oncology</i> , 2011, 5, 113-115.	4.6	2
147	Abstract CT098: Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies. , 2017, , .		2
148	Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP).. <i>Journal of Clinical Oncology</i> , 2018, 36, 185-185.	1.6	2
149	Intravaginal amputation of the uterine cervix with frozen section examination of the endocervical margin: a review of 414 consecutive patients. <i>International Journal of Gynecological Cancer</i> , 1996, 6, 452-455.	2.5	1
150	Surgical Management for Prophylactic Oophorectomy in Women with an Inherited Risk of Ovarian Cancer. <i>Tumori</i> , 2001, 87, 16-17.	1.1	1
151	Is Systemic Disease in the Coelomic Epithelium Associated With BRCA1 Germline Mutations?. <i>Journal of the National Cancer Institute</i> , 2004, 96, 488-489.	6.3	1
152	A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110 α in cell lines and tumor tissues. <i>Analyst</i> , The, 2021, 146, 6566-6575.	3.5	1
153	Abstract 3389: Determining optimal conditions for collection and processing of metastatic liver biopsies collected for a multicenter, prospective study to identify biomarkers of clinical resistance to first-line therapy in metastatic colorectal cancer. , 2012, , .		1
154	Molecular testing in Cutaneous Melanoma. , 2014, , 363-374.		1
155	Direct and Precise Measurement of Bevacizumab Levels in Human Plasma Based on Controlled Methionine Oxidation and Multiple Reaction Monitoring. <i>ACS Pharmacology and Translational Science</i> , 2020, 3, 1304-1309.	4.9	1
156	Importance of Adequate qPCR Controls in Infection Control. <i>Diagnostics</i> , 2021, 11, 2373.	2.6	1
157	Omics in melanoma "what have we learnt and what is the potential impact for patient management?. <i>European Journal of Cancer</i> , Supplement, 2007, 5, 423-424.	2.2	0
158	EORTC Melanoma Group achievements. <i>European Journal of Cancer</i> , Supplement, 2012, 10, 112-119.	2.2	0
159	Abstract 4835: Gonosome-linked expression of PPP2R3B in cutaneous melanoma correlates with distant metastasis free survival. , 2011, , .		0
160	Abstract 5534: Building the organization framework for biopsy-driven translational research: The Quebec Clinical Research Organization in Cancer (Q-CROC) experience. , 2012, , .		0
161	Abstract B24: De novo and acquired resistance to first-line standard therapy in colorectal cancer: from cell lines to metastatic tumors. <i>Clinical Cancer Research</i> , 2012, 18, B24-B24.	7.0	0
162	One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 9062-9062.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Impact of the epigenetic modulator BORIS on sensitivity of melanoma cells to UV-induced DNA damage.. Journal of Clinical Oncology, 2017, 35, e21077-e21077.	1.6	0
164	Abstract 5528: The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. , 2017, , .		0
165	Multi-platform characterization of cutaneous melanoma from patients treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2018, 36, e15071-e15071.	1.6	0
166	Molecular immunoimaging improves tumor detection in head and neck cancer. FASEB Journal, 2022, 36, e22092.	0.5	0
167	The longitudinal impact of COVID-19 on the diagnosis and treatment of lung cancer at a Canadian academic center: Interim analysis from a retrospective chart review.. Journal of Clinical Oncology, 2022, 40, e18737-e18737.	1.6	0
168	Immuno-multiple reaction monitoring (iMRM) for quantitation of PD-L1 and PD-1-signaling proteins in non-small cell lung carcinoma (NSCLC).. Journal of Clinical Oncology, 2022, 40, 2627-2627.	1.6	0